Warning: fopen(/home/virtual/colon/journal/upload/ip_log/ip_log_2025-04.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96
1Department of Surgery, Amsterdam UMC, Amsterdam, the Netherlands
2Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, the Netherlands
3Department of Surgery and Cancer, Imperial College London, London, UK
© 2025 The Korean Society of Coloproctology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflict of interest
James Kinross is a shareholder in SurgEase Innovations Ltd. No other conflict of interest relevant to this article was reported.
Funding
Roel Hompes has received funding from SurgEase Innovations Ltd for the role of principal investigator of this study. All fees were paid to the institution.
Author contributions
Conceptualization: WL, RH; Data curation: RH, JT, JKW, WAB, SS, JK; Formal analysis: all authors; Funding acquisition: RH; Investigation: RH, JT, JKW, WAB, SS, JK; Methodology: WL, RH; Project administration: DJN; Supervision: DJN; Writing–original draft: DJN; Writing–review & editing: all authors. All authors read and approved the final manuscript.
Characteristic | Value (n=35) |
---|---|
Sex | |
Male | 20 (57.1) |
Female | 15 (42.9) |
Age (yr) | 65 (57–72) |
ASA physical status | |
I, II | 29 (82.9) |
III, IV | 6 (17.1) |
Body mass index (kg/m2) | 25.2±3.7 |
Indications for surgery | |
Rectal cancer | 31 (88.6) |
Diverticular disease | 2 (5.7) |
Locally advanced ovarian cancer | 1 (2.9) |
Hartmann procedure reversal | 1 (2.9) |
TNM staginga (n=32) | |
I | 8 (25.0) |
II | 9 (28.1) |
III | 12 (37.5) |
IV | 3 (9.4) |
Neoadjuvant treatment (n=32) | |
None | 19 (59.4) |
Chemoradiotherapy | 7 (21.9) |
Chemotherapy | 2 (6.3) |
Radiotherapy | 4 (12.5) |
Surgical detail | |
Surgical procedure | |
TME | 5 (14.3) |
TaTME | 18 (51.4) |
PME | 11 (31.4) |
Hartmann procedure reversal | 1 (2.9) |
Surgical approach | |
Open | 2 (5.7) |
Laparoscopic | 22 (62.9) |
Robot-assisted | 10 (28.6) |
Conversion to open | 1 (2.9) |
Diverting ostomy | 15 (42.9) |
Distance of anastomosis to ARJ (cm) | 3 (1–10) |
Values are presented as number (%), median (interquartile range), or mean±standard deviation. Percentages may not total 100 due to rounding.
ASA, American Society of Anesthesiologists; TME, total mesorectal excision; TaTME, transanal total mesorectal excision; PME, partial mesorectal excision; ARJ, anorectal junction.
aAccording to the TNM Classification of Malignant Tumours, 8th Edition [16].
Characteristic | Value (n=35) |
---|---|
Sex | |
Male | 20 (57.1) |
Female | 15 (42.9) |
Age (yr) | 65 (57–72) |
ASA physical status | |
I, II | 29 (82.9) |
III, IV | 6 (17.1) |
Body mass index (kg/m2) | 25.2±3.7 |
Indications for surgery | |
Rectal cancer | 31 (88.6) |
Diverticular disease | 2 (5.7) |
Locally advanced ovarian cancer | 1 (2.9) |
Hartmann procedure reversal | 1 (2.9) |
TNM staging |
|
I | 8 (25.0) |
II | 9 (28.1) |
III | 12 (37.5) |
IV | 3 (9.4) |
Neoadjuvant treatment (n=32) | |
None | 19 (59.4) |
Chemoradiotherapy | 7 (21.9) |
Chemotherapy | 2 (6.3) |
Radiotherapy | 4 (12.5) |
Surgical detail | |
Surgical procedure | |
TME | 5 (14.3) |
TaTME | 18 (51.4) |
PME | 11 (31.4) |
Hartmann procedure reversal | 1 (2.9) |
Surgical approach | |
Open | 2 (5.7) |
Laparoscopic | 22 (62.9) |
Robot-assisted | 10 (28.6) |
Conversion to open | 1 (2.9) |
Diverting ostomy | 15 (42.9) |
Distance of anastomosis to ARJ (cm) | 3 (1–10) |
Finding | Value (n=35) |
---|---|
Bedside endoscopic inspection of the anastomosis | |
Healing of the anastomosis on POD 3, 4, or 5 | |
Suspected anastomotic leakage | 3 (8.6) |
Normal healing tendency | 32 (91.4) |
Uncertain | 0 (0) |
Level of visibility | |
Incomplete | 5 (14.3) |
Complete visualization | 30 (85.7) |
Level of discomfort during examination | |
No (notable) discomfort | 32 (91.4) |
Mild discomfort | 3 (8.6) |
Severe discomfort | 0 (0) |
Clinical outcome at 90 days after index surgery | |
Anastomotic leakage | 6 (17.1) |
Time to diagnosis (day) | 5 (4–29) |
Mortality | 0 (0) |
Values are presented as number (%), median (interquartile range), or mean±standard deviation. Percentages may not total 100 due to rounding. ASA, American Society of Anesthesiologists; TME, total mesorectal excision; TaTME, transanal total mesorectal excision; PME, partial mesorectal excision; ARJ, anorectal junction. According to the TNM Classification of Malignant Tumours, 8th Edition [
Values are presented as number (%) or median (interquartile range). POD, postoperative day.